RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mereo BioPharma Group Stock

Mereo BioPharma Group Revenue 2025

Mereo BioPharma Group Revenue

23.39 M USD

Ticker

MREO

ISIN

US5894921072

WKN

A2PEYJ

In 2025, Mereo BioPharma Group's sales reached 23.39 M USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Mereo BioPharma Group Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2030e489.621,52
2029e364.192,04
2028e229.923,23
2027e65.4411,35
2026e35.6320,84
2025e23.3931,75
2024--
20231074,26
2022--
202150.1450,89
2020--
2019--
2018--
2017--
2016--
2015--

Mereo BioPharma Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mereo BioPharma Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mereo BioPharma Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mereo BioPharma Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mereo BioPharma Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mereo BioPharma Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mereo BioPharma Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mereo BioPharma Group’s growth potential.

Mereo BioPharma Group Revenue, EBIT and net profit per share

DateMereo BioPharma Group RevenueMereo BioPharma Group EBITMereo BioPharma Group Net Income
2030e489.62 M undefined0 undefined201.13 M undefined
2029e364.19 M undefined196.84 M undefined148.24 M undefined
2028e229.92 M undefined95.85 M undefined80.65 M undefined
2027e65.44 M undefined-7.18 M undefined-19.54 M undefined
2026e35.63 M undefined-22.41 M undefined-14 M undefined
2025e23.39 M undefined-29.56 M undefined-45.28 M undefined
20240 undefined-47.36 M undefined-43.25 M undefined
202310 M undefined-28.42 M undefined-29.47 M undefined
20220 undefined-53.68 M undefined-42.13 M undefined
202150.14 M undefined-28.79 M undefined17.5 M undefined
20200 undefined-48.17 M undefined-209.8 M undefined
20190 undefined-50.43 M undefined-44.46 M undefined
20180 undefined-45.96 M undefined-42.69 M undefined
20170 undefined-45.3 M undefined-38.8 M undefined
20160 undefined-36.18 M undefined-28.39 M undefined
20150 undefined-13.12 M undefined-12.19 M undefined

Mereo BioPharma Group stock margins

The Mereo BioPharma Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mereo BioPharma Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mereo BioPharma Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mereo BioPharma Group's sales revenue. A higher gross margin percentage indicates that the Mereo BioPharma Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mereo BioPharma Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mereo BioPharma Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mereo BioPharma Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mereo BioPharma Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mereo BioPharma Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mereo BioPharma Group Margin History

Mereo BioPharma Group Gross marginMereo BioPharma Group Profit marginMereo BioPharma Group EBIT marginMereo BioPharma Group Profit margin
2030e74.26 %0 %41.08 %
2029e74.26 %54.05 %40.7 %
2028e74.26 %41.69 %35.08 %
2027e74.26 %-10.97 %-29.87 %
2026e74.26 %-62.92 %-39.3 %
2025e74.26 %-126.4 %-193.64 %
202474.26 %0 %0 %
202374.26 %-284.16 %-294.66 %
202274.26 %0 %0 %
202150.89 %-57.42 %34.9 %
202074.26 %0 %0 %
201974.26 %0 %0 %
201874.26 %0 %0 %
201774.26 %0 %0 %
201674.26 %0 %0 %
201574.26 %0 %0 %

Mereo BioPharma Group Aktienanalyse

What does Mereo BioPharma Group do?

Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo BioPharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Mereo BioPharma Group's Sales Figures

The sales figures of Mereo BioPharma Group originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Mereo BioPharma Group’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Mereo BioPharma Group's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Mereo BioPharma Group’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Mereo BioPharma Group stock

How much revenue did Mereo BioPharma Group generate this year?

Mereo BioPharma Group has achieved a revenue of 23.39 M USD this year.

How much was the turnover of the company Mereo BioPharma Group compared to the previous year?

The revenue of Mereo BioPharma Group has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Mereo BioPharma Group?

The revenue of Mereo BioPharma Group is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Mereo BioPharma Group measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Mereo BioPharma Group so important for investors?

The revenue of Mereo BioPharma Group is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Mereo BioPharma Group pay?

Over the past 12 months, Mereo BioPharma Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mereo BioPharma Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Mereo BioPharma Group?

The current dividend yield of Mereo BioPharma Group is .

When does Mereo BioPharma Group pay dividends?

Mereo BioPharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mereo BioPharma Group?

Mereo BioPharma Group paid dividends every year for the past 0 years.

What is the dividend of Mereo BioPharma Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mereo BioPharma Group located?

Mereo BioPharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mereo BioPharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mereo BioPharma Group from 7/9/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/9/2025.

When did Mereo BioPharma Group pay the last dividend?

The last dividend was paid out on 7/9/2025.

What was the dividend of Mereo BioPharma Group in the year 2024?

In the year 2024, Mereo BioPharma Group distributed 0 USD as dividends.

In which currency does Mereo BioPharma Group pay out the dividend?

The dividends of Mereo BioPharma Group are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mereo BioPharma Group

Our stock analysis for Mereo BioPharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mereo BioPharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.